Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)

Condition:   Non Hodgkin Lymphoma Intervention:   Drug: Tenalisib, Sponsor:   Rhizen Pharmaceuticals SA Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials